<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175922">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805441</url>
  </required_header>
  <id_info>
    <org_study_id>12422</org_study_id>
    <secondary_id>H8R-MC-HJAQ</secondary_id>
    <nct_id>NCT00805441</nct_id>
  </id_info>
  <brief_title>A Study in the Treatment of Alcohol Dependence.</brief_title>
  <official_title>A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with
      placebo in a 12-week trial that includes Medical Management. This study is an outpatient
      study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will
      be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing
      for twelve weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in heavy drinking days.</measure>
    <time_frame>Baseline, week 4, week 8, week 12 and week 16.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent days abstinent per month.</measure>
    <time_frame>baseline, week 4, week 8, week 12 and week 16.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drinks per drinking day during a month.</measure>
    <time_frame>baseline, week 4, week 8, week 12 and week 16.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinker inventory of Consequences (DrInC)</measure>
    <time_frame>baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol Urge questionnaire - change from baseline.</measure>
    <time_frame>baseline, week 1, week 2, week 3, week 4, week 6, week 8, week 10 and week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn Alcohol Craving Scale - change from baseline.</measure>
    <time_frame>baseline, week 1, week 2, week 3, week 4, week 6, week 8, week 10 and week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II (BDI-II) - change from baseline.</measure>
    <time_frame>baseline, week 1, week 2, week 3, week 4, week 6, week 8, week 10 and week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Index - change from baseline.</measure>
    <time_frame>baseline, week 6 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl transferase -change from baseline.</measure>
    <time_frame>baseline, week 1, week 2, week 3, week 4, week 6, week 8, week 10 and week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma carbohydrate deficient transferring (CDT) - change from baseline.</measure>
    <time_frame>baseline, week 1, week 2, week 3, week 4, week 6, week 8, week 10 and week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health outcomes (Short Form 12)</measure>
    <time_frame>baseline and week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY686017</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY686017</intervention_name>
    <description>50 mg daily by oral route for 12 weeks</description>
    <arm_group_label>LY686017</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily by oral route for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have Alcohol Dependence.

          -  Are men or women who are ambulatory outpatients between 21 to 65 years of age
             (inclusive) showing evidence of living in a non-custodial stable residence and with
             no plans to move during the next 5 months.

          -  Females of childbearing potential (not surgically sterilized and between menopause)
             must test negative for pregnancy at the time of enrollment based on a pregnancy test.
             They must agree to use a reliable method of birth control during the study and for 2
             months following the last dose of study drug.

          -  Drink on average more than 14 drinks (women) or 21 drinks (men) per week with at
             least 2 heavy drinking days per week.

          -  Endorse abstinence or reduction in drinking as an interim goal toward abstinence.

        Exclusion Criteria:

          -  Are investigator site personnel directly affiliated with this study and/or their
             immediate families.

          -  Are Lilly employees.

          -  Are currently enrolled in or discontinued within the last 30 days from a clinical
             trial.

          -  Have experienced an acute alcohol withdrawal syndrome within the past 6 months or are
             currently or during this study at significant risk of suffering an acute alcohol
             withdrawal syndrome.

          -  Have a history of serious head injury, neoplasm or hemorrhage, prior seizure (other
             than a history of childhood febrile seizure), or other condition that would place the
             subject at increased risk for seizures.

          -  Are taking or have taken anticonvulsant medications for seizures.

          -  Are diagnosed with substance dependence or substance abuse other than alcohol,
             cannabis, nicotine, or caffeine within 12 months prior to first visit.

          -  Are receiving medications or intensive behavioral or psychological therapy delivered
             by a licensed or certified alcohol treatment specialist for alcohol dependence.

          -  Have signs and symptoms or an active illness within the past 2 weeks of first visit
             that meet criteria diagnosis of Major Depressive Disorder. In addition, meet criteria
             as diagnosis for any comorbid Axis I disorders (such as anxiety disorders, OCD, PTSD,
             panic disorder, or dysthymia).

          -  Have a positive urine drug screen for any non-prescribed substances of abuse.

          -  Have a serious medical illness including but not limited to any cardiovascular,
             hepatic,respiratory, hematological, endocrine, or neurological disease, or any
             clinically significant laboratory abnormality.

          -  Ever had electroconvulsive therapy (ECT).

          -  Have abnormal thyroid stimulating hormone (TSH) concentrations or are taking thyroid
             supplements.

          -  Have a history of cirrhosis or laboratory evidence of hepatocellular injury.

          -  An abnormality in serum Prothrombin time.

          -  Are unable to make themselves available for the duration of the study or abide by
             study procedures and restrictions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>76260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Havertown</city>
        <state>Pennsylvania</state>
        <zip>19083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>May 27, 2010</lastchanged_date>
  <firstreceived_date>December 5, 2008</firstreceived_date>
  <firstreceived_results_disposition_date>May 27, 2010</firstreceived_results_disposition_date>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <keyword>Alcoholic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
